Mark C. Gebhardt focuses mostly in the field of Stress fractures, narrowing it down to matters related to Radiology and, in some cases, Magnetic resonance imaging. He combines Magnetic resonance imaging and Radiology in his research. Surgery is frequently linked to Cadaveric spasm in his study. Mark C. Gebhardt performs integrative study on Lesion and Pathology in his works. His Pathology study frequently draws connections to other fields, such as Soft tissue. His work often combines Soft tissue and Cancer studies. His multidisciplinary approach integrates Cancer and Lesion in his work. Mark C. Gebhardt conducts interdisciplinary study in the fields of Radiation therapy and Sarcoma through his research. He undertakes interdisciplinary study in the fields of Sarcoma and Soft tissue sarcoma through his research.
Mark C. Gebhardt performs integrative study on Surgery and Amputation. Mark C. Gebhardt merges Pathology with Immunology in his research. Mark C. Gebhardt integrates many fields, such as Immunology and Pathology, in his works. Mark C. Gebhardt regularly ties together related areas like Chemotherapy in his Internal medicine studies. Chemotherapy is frequently linked to Internal medicine in his study. Mark C. Gebhardt incorporates Biochemistry and Molecular biology in his studies. While working on this project, Mark C. Gebhardt studies both Molecular biology and Biochemistry. His study deals with a combination of Genetics and Cancer research. He connects Cancer research with Genetics in his study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system.
William F. Enneking;William Dunham;Mark C. Gebhardt;Martin Malawar.
Clinical Orthopaedics and Related Research (1993)
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Holcombe E Grier;Mark D Krailo;Nancy J Tarbell;Michael P Link.
The New England Journal of Medicine (2003)
p53 functions as a cell cycle control protein in osteosarcomas.
L Diller;J Kassel;C E Nelson;M A Gryka.
Molecular and Cellular Biology (1990)
Biology and Therapeutic Advances for Pediatric Osteosarcoma
Neyssa Marina;Mark Gebhardt;Lisa Teot;Richard Gorlick.
Long-term results of allograft replacement in the management of bone tumors.
Henry Mankin;Mark Gebhardt;L. Jennings;Dempsey Springfield.
Clinical Orthopaedics and Related Research (1996)
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Paul A. Meyers;Cindy L. Schwartz;Mark D. Krailo;John H. Healey.
Journal of Clinical Oncology (2008)
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Paul A. Meyers;Cindy L. Schwartz;Mark Krailo;Eugenie S. Kleinerman.
Journal of Clinical Oncology (2005)
Infection in bone allografts. Incidence, nature, and treatment.
C F Lord;M C Gebhardt;W W Tomford;H J Mankin.
Journal of Bone and Joint Surgery, American Volume (1988)
Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment.
Daniel Rosenthal;Francis Hornicek;Michael Wolfe;L. Jennings.
Journal of Bone and Joint Surgery, American Volume (1998)
Osteoid osteoma: percutaneous treatment with radiofrequency energy.
Daniel I Rosenthal;Francis J Hornicek;Martin Torriani;Mark C Gebhardt.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: